Hexagon Bio
Scientist in Pharmacology supporting the development and characterization of next-generation antibody-drug conjugates (ADCs) with novel natural-product payloads. Hands-on, laboratory-based role located in Menlo Park, CA, working closely with interdisciplinary teams to advance ADC candidates from in vitro evaluation toward translational studies.
Hexagon Bio is a biotechnology company focused on developing novel payload mechanisms for antibody-drug conjugates (ADCs) to treat cancer. The company aims to overcome resistance to existing ADC payloads and expand ADC indications through its pipeline and scientific platform. Hexagon Bio operates in the biotech and oncology therapeutics industry.
Wilson Sonsini Advises Hexagon Bio on Multimillion-Dollar Joint Venture with Corteva
Dec 17, 2025
Corteva, Hexagon Bio Form Multi-Million Dollar JV to Power Next-Generation of Nature Inspired Solutions
Dec 16, 2025
Corteva, Hexagon Bio launch joint venture to develop crop protection
Dec 16, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Hexagon Bio.
Hexagon Bio & Corteva Form JV to Advance Nature-Inspired Crop Protection
Dec 17, 2025
Senior Scientist
Systimmune
Associate Director, ADC platform in Oncology Drug Discovery
Novartis
Scientist - RC Discovery Biology
AstraZeneca
Scientist, Immuno-Oncology
Systimmune
Senior Principal Scientist, In Vitro Pharmacology
Flagship Pioneering, Inc.
Scientist - Cell Biology - BioTDR
Eli Lilly and Company